Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: A network meta-analysis

Gastroenterology

Volumn 148, Issue 2, 2015, Pages 344-354.e5

  Hazlewood, Glen S ^a   Rezaie, Ali ^c   Borman, Meredith ^a   Panaccione, Remo ^a   Ghosh, Subrata ^a   Seow, Cynthia H ^a,b   Kuenzig, Ellen ^b   Tomlinson, George ^d   Siegel, Corey A ^e   Melmed, Gil Y ^c   Kaplan, Gilaad G ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Anti TNF Therapy; IBD; Immunosuppressive Agents; Network Meta analysis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; VEDOLIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY;

BIOLOGICAL PRODUCTS; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921325308     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.10.011     Document Type: Article

References (61)

1. N.A. Molodecky, I.S. Soon, and D.M. Rabi Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 2012 46 54.e42 quiz e30
2. M.D. Kappelman, S.L. Rifas-Shiman, and C.Q. Porter Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults Gastroenterology 135 2008 1907 1913
3. A.D. Frolkis, J. Dykeman, and M.E. Negron Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies Gastroenterology 145 2013 996 1006
4. B.G. Feagan, M. Lemann, and R. Befrits Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report Inflamm Bowel Dis 18 2012 152 160
5. G.Y. Melmed, B.M. Spiegel, and B. Bressler The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all Clin Gastroenterol Hepatol 8 2010 655 659
6. W.J. Sandborn, B.G. Feagan, and P. Rutgeerts Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 2013 711 721
7. A.S. Cheifetz, G.Y. Melmed, and B. Spiegel Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups Inflamm Bowel Dis 18 2012 2294 2300
8. Institute of Medicine (IOM) Initial national priorities for comparative effectiveness research 2009 The National Academies Press Washington, DC
9. J.P. Jansen, R. Fleurence, and B. Devine Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 Value Health 14 2011 417 428
10. T. Dassopoulos, S. Sultan, and Y.T. Falck-Ytter American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease Gastroenterology 145 2013 1464 1478 e1-5
11. P. Juillerat, S.K. Wasan, and S.A. Fowler Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals Inflamm Bowel Dis 19 2013 2457 2463
12. B.W. Behm, and S.J. Bickston Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 1 2008 CD006893
13. N. Chande, D.J. Tsoulis, and J.K. MacDonald Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Cochrane Database Syst Rev 4 2013 CD000545
14. J.W. McDonald, D.J. Tsoulis, and J.K. Macdonald Methotrexate for induction of remission in refractory Crohn's disease Cochrane Database Syst Rev 12 2012 CD003459
15. V. Patel, J.K. Macdonald, and J.W. McDonald Methotrexate for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 4 2009 CD006884
16. E. Prefontaine, J.K. Macdonald, and L.R. Sutherland Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Cochrane Database Syst Rev 6 2010 CD000545
17. D.J. Spiegelhalter, K.R. Abrams, and J.P. Myles Bayesian approaches to clinical trials and health-care evaluation 2004 John Wiley & Sons Ltd Chichester, England
18. A.E. Ades, M. Sculpher, and A. Sutton Bayesian methods for evidence synthesis in cost-effectiveness analysis Pharmacoeconomics 24 2006 1 19
19. S. Ardizzone, S. Bollani, and G. Manzionna Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study Dig Liver Dis 35 2003 619 627
20. S. Arora, W. Katkov, and J. Cooley Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial Hepatogastroenterology 46 1999 1724 1729
21. S. Candy, J. Wright, and M. Gerber A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
22. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
23. J.F. Colombel, W.J. Sandborn, and P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65
24. K. Ewe, A.G. Press, and C.C. Singe Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 105 1993 367 372
25. B.G. Feagan, R.N. Fedorak, and E.J. Irvine A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
26. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin Clin Gastroenterol Hepatol 6 2008 1370 1377
27. B.G. Feagan, J.W. McDonald, and R. Panaccione Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease Gastroenterology 146 2014 681 688.e1
28. B.G. Feagan, J. Rochon, and R.N. Fedorak Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
29. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
30. S.B. Hanauer, W.J. Sandborn, and P. Rutgeerts Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2006 323 332
31. M. Lemann, J.Y. Mary, and B. Duclos Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 2006 1054 1061
32. Mantzaris G, P. P, A. K, et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid-dependent Crohn's disease. Gastroenterology 2004;126:A54.
33. J. Mate-Jimenez, C. Hermida, and J. Cantero-Perona 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease Eur J Gastroenterol Hepatol 12 2000 1227 1233
34. R. Oren, M. Moshkowitz, and S. Odes Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial Am J Gastroenterol 92 1997 2203 2209
35. J. Panes, A. Lopez-Sanroman, and F. Bermejo Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease Gastroenterology 145 2013 766 774.e1
36. W. Reinisch, J. Panes, and M. Lemann A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease Am J Gastroenterol 103 2008 2284 2292
37. J.L. Rosenberg, B. Levin, and A.J. Wall A controlled trial of azathioprine in Crohn's disease Am J Dig Dis 20 1975 721 726
38. P. Rutgeerts, G. D'Haens, and S. Targan Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
39. P. Rutgeerts, G. Van Assche, and W.J. Sandborn Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial Gastroenterology 142 2012 1102 1111.e2
40. W.J. Sandborn, B.G. Feagan, and S. Stoinov Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238
41. W.J. Sandborn, S.B. Hanauer, and P. Rutgeerts Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239
42. W.J. Sandborn, P. Rutgeerts, and R. Enns Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 146 2007 829 838
43. W.J. Sandborn, S. Schreiber, and B.G. Feagan Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial Clin Gastroenterol Hepatol 9 2011 670 678.e3
44. B.E. Sands, B.G. Feagan, and P. Rutgeerts Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment had failed Gastroenterology 147 2014 618 627.e3
45. S. Schreiber, M. Khaliq-Kareemi, and I.C. Lawrance Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 2007 239 250
46. S. Schreiber, P. Rutgeerts, and R.N. Fedorak A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 2005 807 818
47. O. Schroder, I. Blumenstein, and J. Stein Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study Eur J Gastroenterol Hepatol 18 2006 11 16
48. S.R. Targan, S.B. Hanauer, and S.J. van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029 1035
49. M. Watanabe, T. Hibi, and K.G. Lomax Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease J Crohns Colitis 6 2012 160 173
50. J.M. Willoughby, J. Beckett, and P.J. Kumar Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 944 947
51. D.H. Winship, R.W. Summers, and J.W. Singleton National Cooperative Crohn's Disease Study: study design and conduct of the study Gastroenterology 77 1979 829 842
52. T.A. Winter, J. Wright, and S. Ghosh Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study Aliment Pharmacol Ther 20 2004 1337 1346
53. W.J. Sandborn, S.B. Hanauer, and S. Katz Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
54. W.J. Sandborn, B.G. Feagan, and G. Radford-Smith CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial Gut 53 2004 1485 1493
55. R.W. Stidham, T.C. Lee, and P.D. Higgins Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease Aliment Pharmacol Ther 39 2014 1349 1362
56. A.C. Moss, V. Brinks, and J.F. Carpenter Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors Aliment Pharmacol Ther 38 2013 1188 1197
57. J. Jones, G. Kaplan, and L. Peyrin-Biroulet Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data United European Gastroenterology Week 1 2013 A16
58. T. Wyant, T. Leach, and S. Sankoh Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results Gut 2014 Epub ahead of print
59. C. Su, G.R. Lichtenstein, and K. Krok A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease Gastroenterology 126 2004 1257 1269
60. A. Ades ISPOR states its position on network meta-analysis Value Health 14 2011 414 416
61. G.W. Moran, M.F. Dubeau, and G.G. Kaplan Phenotypic features of Crohn's disease associated with failure of medical treatment Clin Gastroenterol Hepatol 12 2014 434 442